Economic and clinical value has become the basis for both differentiation and maintaining premium pricing, and the importance of the economic and clinical value case is likely only to increase. This trend is truly global in scope, applies to multiple key stakeholder groups (payers, physicians, and patients), and is particularly apparent in high-cost therapeutic areas where large numbers of new and costly therapies are being introduced for treatment of chronic diseases.

Moving forward, economic and clinical value must serve as the foundation for all portfolio management decisions. Companies must also have processes and capabilities in place to focus on economic and clinical value as early as possible in the product development cycle.